[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![BioTechVisions Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1885166346230784002.png) BioTech Visionary [@BioTechVisions](/creator/twitter/BioTechVisions) on x XX followers
Created: 2025-07-23 19:37:01 UTC

🛡️ Arrowhead Stands Firm on $825M Sarepta Deal Amid Pharma Turbulence

Arrowhead isn’t backing down. Despite compliance issues and safety-related delays at Sarepta, Arrowhead says it's on track to receive $300M in milestone payments by the end of the year—part of a deal that could be worth up to $825M 💰.

While Sarepta’s stock is down, Arrowhead reassures stakeholders that Sarepta remains committed—and if they fail to pay, Arrowhead has recourse to reclaim the licensed IP. Still, analysts warn that Arrowhead may need a third partner to fund these programs if Sarepta stumbles.

This deal isn’t just about funding—it's a model of how structured biotech partnerships can navigate partner volatility. 🔄

#Biotech #Arrowhead #Sarepta #RNAi #LicensingDeals #StrategicPartnerships

![](https://pbs.twimg.com/media/GwkPPWRaQAA6MUq.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948105088951832847/c:line.svg)

**Related Topics**
[$300m](/topic/$300m)
[$825m](/topic/$825m)

[Post Link](https://x.com/BioTechVisions/status/1948105088951832847)